Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)

• Main Authors: Timothy D. Owens (Author), Patrick F. Smith (Author), Andrew Redfern (Author), Yan Xing (Author), Jin Shu (Author), Dane E. Karr (Author), Sonja Hartmann (Author), Michelle R. Francesco (Author), Claire L. Langrish (Author), Philip A. Nunn (Author), Steven G. Gourlay (Author)
• Format: Book
• Published: Wiley, 2022-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Bruton's tyrosine kinase (BTK), expressed in B cells and cells of innate immunity, including microglia, is an essential signaling element downstream of the B‐cell receptor and Fc‐receptors. Tolebrutinib (PRN2246, SAR442168) is a potent BTK inhibitor that covalently binds the kinase, re...